Prostate cancer in renal transplant recipients

Nephrology Dialysis Transplantation

Volumn 23, Issue 7, 2008, Pages 2374-2380

  Kleinclauss, François ^a,b,k   Gigante, Marc ^a,c   Neuzillet, Yann ^a,d   Mouzin, Marc ^a,e   Terrier, Nicolas ^a,f   Salomon, Laurent ^a,g   Iborra, François ^a,h   Petit, Jacques ^a,i   Cormier, Luc ^a,j   Lechevallier, Eric ^a,d  

^a Renal Transplantation Committee   (France)

^b HÔPITAL SAINT JACQUES   (France)

^c UNIVERSITY HOSPITAL OF NICE   (France)

^d Child and Adolescent Psychopathology Unit Salvator Hospital Public Assistance Marseille Hospitals University Aix Marseille II   (France)

^e CHU RANGUEIL   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g HENRI MONDOR HOSPITAL   (France)

^h LAPEYRONIE HOSPITAL   (France)

ⁱ AMIENS UNIVERSITY HOSPITAL   (France)

^j CHU NANCY BRABOIS   (France)

^k UNIVERSITY HOSPITAL OF BESANÇON   (France)

more..

Author keywords

Cancer; Immunosuppression; Kidney; Prostate; Transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID;

ADULT; AGED; ARTICLE; CANCER RISK; COMBINATION CHEMOTHERAPY; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SIDE EFFECT;

AGED; AZATHIOPRINE; CALCINEURIN; FRANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MASS SCREENING; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOPHENOLIC ACID; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 46849112208     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn008     Document Type: Article

References (41)

1. Danpanich E, Kasiske BL. Risk factors for cancer in renal transplant recipients. Transplantation 1999; 68: 1859-1864
2. Penn I. Neoplasic Complications of Organ Transplantation. Malden, MA: Blackwell, 1999, 770
3. Kasiske BL, Snyder JJ, Gilbertson DT et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905-913
4. Kessler M, Jay N, Molle R et al. Excess risk of cancer in renal transplant patients. Transpl Int 2006; 19: 908-914
5. US Renal Data System (USRDS). Annual Report: Atlas of End Stage Renal Disease in the United States. In Health NIo ed. National Institutes of Diabetes and Digestive and Kidney Disease, Besthesda, MD, 2007
6. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1998; 147-158
7. Birkeland SA, Storm HH, Lamm LU et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995; 60: 183-189
8. Cormier L, Lechevallier E, Barrou B et al. Diagnosis and treatment of prostate cancers in renal-transplant recipients. Transplantation 2003; 75: 237-239
9. Muruve NA, Shoskes DA. Genitourinary malignancies in solid organ transplant recipients. Transplantation 2005; 80: 709-716
10. Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-628
11. Ducloux D, Carron PL,Motte G et al. Lymphocyte subsets and assessment of cancer risk in renal transplant recipients. Transpl Int 2002; 15: 393-396
12. Guichard G, Rebibou JM, Ducloux D et al. Lymphocyte subsets in renal transplant recipients with de novo genitourinary malignancies Urol Int 2007; 80: 257-263
13. Hojo M, Morimoto T, Maluccio M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-534
14. Pollard M. Enhancement of metastasis of prostate adenocarcinoma cells by immune-suppressive cyclosporine A. Cancer Lett 1997; 111: 221-224
15. Wikstrom P, Stattin P, Franck-Lissbrant I et al. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998; 37: 19-29
16. Taylor AE, Shuster S. Skin cancer after renal transplantation: the causal role of azathioprine. Acta Derm Venereol 1992; 72: 115-119
17. David KM, Morris JA, Steffen BJ et al. Mycophenolate mofetil versus azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin Transplant 2005; 19: 279-285
18. Robson R, Cecka JM, Opelz G et al. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5: 2954-2960
19. Ekberg H, Grinyo J, Nashan B et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR study. Am J Transplant 2007; 7: 560-570
20. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581-589
21. Kauffman HM, Cherikh WS, Cheng Y et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-889
22. Campistol JM, Albanell J, Arns W et al. Use of proliferation signal inhibitors in the management of post-transplant malignancies - clinical guidance. Nephrol Dial Transplant 2007; 22 (Suppl 1): i36-i41
23. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005; 65: 2825-2831
24. Cao C, Subhawong T, Albert JM et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006; 66: 10040-10047
25. Sheil AG. Patterns of malignancies following renal transplantation. Transplant Proc 1999; 31: 1263-1265
26. Kauffman HM, Cherikh WS, McBride MA et al. Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int 2006; 19: 607-620
27. Konety BR, Tewari A, Howard RJ et al. (Urologic Society for Transplantation and Vascular Surgery). Prostate cancer in the posttransplant population. Urology 1998; 52: 428-432
28. Kriteman LS, O'Brien DP, Clarke HS et al. Prostate cancer in renal transplant recipients. J Urol 1999; 161: 381
29. Soulie M, Barre C, Beuzeboc P et al. Prostatic cancer. Prog Urol 2004; 14: 913, 915-955
30. Postma R, Schroder FH, van Leenders GJ et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) - Section Rotterdam. A comparison of two rounds of screening. Eur Urol 2007; 52: 89-97
31. Roobol MJ, Zappa M, Maattanen L et al. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC). Prostate 2007; 67: 439-446
32. Crum NF, Spencer CR, Amling CL. Prostate carcinoma among men with human immunodeficiency virus infection. Cancer 2004; 101: 294-299
33. Levinson A, Nagler EA, Lowe FC. Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus. Urology 2005; 65: 91-94
34. Van Der Cruijsen-Koeter IW, Vis AN, Roobol MJ et al. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam. J Urol 2005; 174: 121-125
35. Kleinclauss F, Kleinclauss C, Bittard H. Erectile dysfunction in renal failure patients and renal transplant recipients. Prog Urol 2005; 15: 447-455; discussion 455-446
36. Palmer BF. Sexual dysfunction in uremia. J Am Soc Nephrol 1999; 10: 1381-1388
37. Isom-Batz G, Bianco FJ, Jr., Kattan MW et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005; 173: 1935-1937
38. Jenkins FJ, Hayes RB, Jackson A et al. Human herpesvirus 8 seroprevalence among prostate cancer case patients and control subjects. J Infect Dis 2007; 196: 208-211
39. Sutcliffe S, Giovannucci E, Gaydos CA et al. Plasma antibodies against chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2007; 16: 1573-1580
40. Fioriti D, Russo G, Mischitelli M et al. A case of human polyomavirus Bk infection in a patient affected by late stage prostate cancer: could viral infection be correlated with cancer progression? Int J Immunopathol Pharmacol 2007; 20: 405-411
41. Gutierrez-Dalmau A, Campistol JM. The role of proliferation signal inhibitors in post-transplant malignancies. Nephrol Dial Transplant 2007; 22(Suppl 1): i11-i16